These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22618984)

  • 1. Ivacaftor, vismodegib, and ingenol mebutate.
    Hussar DA; Eckel SP
    J Am Pharm Assoc (2003); 2012; 52(3):418-22. PubMed ID: 22618984
    [No Abstract]   [Full Text] [Related]  

  • 2. Ivacaftor.
    Davis PB; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2012 Apr; 11(5):349-50. PubMed ID: 22543461
    [No Abstract]   [Full Text] [Related]  

  • 3. PICATO (ingenol mebutate 0.015% and 0.05% gels): a novel treatment for actinic keratosis.
    Abramovits W; Oquendo M; Vincent KD; Gupta AK
    Skinmed; 2013; 11(2):111-5. PubMed ID: 23745230
    [No Abstract]   [Full Text] [Related]  

  • 4. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
    Mayer M
    Evid Based Med; 2016 Jun; 21(3):83-6. PubMed ID: 26718821
    [No Abstract]   [Full Text] [Related]  

  • 5. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 6. Ivacaftor for patients with cystic fibrosis.
    Wainwright CE
    Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic options for actinic keratosis and basal cell carcinoma.
    Sligh JE
    Semin Cutan Med Surg; 2014 Jun; 33(4 Suppl):S76-80. PubMed ID: 25268601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drugs 2013, Part I.
    Hussar DA
    Nursing; 2013 Feb; 43(2):36-46; quiz 47-8. PubMed ID: 23302940
    [No Abstract]   [Full Text] [Related]  

  • 9. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).
    Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F
    Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Drug Hailed as Major Breakthrough in Cystic Fibrosis.
    Am J Med Genet A; 2020 Jan; 182(1):8-9. PubMed ID: 31825178
    [No Abstract]   [Full Text] [Related]  

  • 11. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
    Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
    [No Abstract]   [Full Text] [Related]  

  • 12. PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.
    Fohner AE; McDonagh EM; Clancy JP; Whirl Carrillo M; Altman RB; Klein TE
    Pharmacogenet Genomics; 2017 Jan; 27(1):39-42. PubMed ID: 27636560
    [No Abstract]   [Full Text] [Related]  

  • 13. Ingenol mebutate (Picato) for actinic keratosis.
    Med Lett Drugs Ther; 2012 Apr; 54(1389):35-6. PubMed ID: 22538622
    [No Abstract]   [Full Text] [Related]  

  • 14. Ingenol mebutate: a new option for actinic keratosis treatment.
    Gras J
    Drugs Today (Barc); 2013 Jan; 49(1):15-22. PubMed ID: 23362492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
    Berman B
    Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label.
    Ratner M
    Nat Biotechnol; 2017 Jul; 35(7):606. PubMed ID: 28700545
    [No Abstract]   [Full Text] [Related]  

  • 17. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry.
    Sawicki GS; Dasenbrook E; Fink AK; Schechter MS
    Ann Am Thorac Soc; 2015 Aug; 12(8):1146-52. PubMed ID: 26073026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Treatment for Cystic Fibrosis.
    Aschenbrenner DS
    Am J Nurs; 2020 Feb; 120(2):21. PubMed ID: 31977412
    [No Abstract]   [Full Text] [Related]  

  • 19. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
    Kaiser J
    Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
    [No Abstract]   [Full Text] [Related]  

  • 20. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.